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Abstract
Background: The progression of breast cancer is increasing at an alarming rate, particularly in western countries.
Meanwhile, the lower incidence in Asian countries could be attributed to the heavy incorporation of green leaves
vegetables or spices in their diets. Murraya koenigii (MK) or often times known as curry leaves are common spice
used mostly in tropical countries. Anti-inflammatory and chemopreventive effects of MK aqueous extract on 4T1
breast cancer cell-challenged mice were evaluated.
Methods: Herein, cytotoxic activity of MK was first tested on 4T1 cells in vitroby MTT assay. Then, in vivo
chemopreventive study was conducted where mice were fed with extracts prior to and after inducing the tumor
(inoculation). Tumor size was monitored post-4T1 inoculation. At the end of experiment, histopathology of tumor
sections, T cell immunophenotyping, tumor nitric oxide level, serum cytokine level and qPCR analysis on expression
of iNOS, iCAM, NF-kB and c-MYC were performed.
Results: MK reduced the tumors’ size and lung metastasis aside from inhibited the viability of 4T1 cells in vitro.
Furthermore, it decreased the level of nitric oxide and inflammation-related cytokines and genes, including iNOS,
iCAM, NF-kB and c-MYC.
Conclusion: The results propose that, MK managed to inhibit the progression of tumor via immunostimulatory
effect and inflammatory reaction within the tumor samples. This suggests that MKconsumption could be a savior in
the search of new chemopreventive agents.
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Background
Breast cancer is the most common type of cancer among
women especiallyin industrialized countries such asEur-
opean countries and the United States. In other develop-
ing countries,for instance, China and India, the relative
incidence of breast cancer is much lower and this
phenomenon has been related to the different lifestylesin
terms of diet and food preparation method [1]. Natural
food ingredients commonly consumed in the Asian diet,
which carries relatively low toxicity have been proposed
as one of the finest chemopreventive strategies to com-
bat cancer [2]. Despite the advance of cancer prevention
including better diagnostic for early detection and used
of anti-estrogenic drugs such as tamoxifen and raloxi-
fene, which resulted in the reduction of breast cancer
incident and mortality, breast cancer is still the most
commonly diagnosed cancer that contributes to the sec-
ond highest caused of cancer associated mortality in
women [1, 2]. Cancer chemoprevention has been defined
as the use of pharmacologic or natural agents to reverse,
suppress, delay or prevent the incident and progression
of carcinogenesis [3]. Herbs have been identified as an
important source of novel bioactive compounds for
medicine development including cancer chemotherapeu-
tic drugs [4]. Lower incident of breast and colon cancer
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in Asia especially India has been correlated with the diet
and natural food ingredients while increasing of breast
cancer incident has been correlated with the change of
life style including consumption of Western high
calorie-dense diet [1].
Murraya koenigii (MK) or commonly known as curry
leaves is a tropical vegetable that is widely used as spice
for seasoning and flavoring in tropical countries. Previ-
ous study has shown that MK was good source of nutri-
ent since it contained high amount of insoluble dietary
fiber (38.8 %), followed by carbohydrate (12.5 %), crude
protein (11.8 %) and crude fat (5.1 %). Besides, MK also
contained high amount of potassium (21.5 mg/g), cal-
cium (20.9 mg/g), phosphate (3.6 mg/g), Magnesium
(3.1 mg/g) and vitamin C (1.2 mg/g) [5]. Traditionally,
MK has been widely used in Ayurveda medicine as
tonic, stomachic and carminative due to its medicinal
properties [6]. MK has been reportedwith immunomod-
ulatory [7], anti-tumor [7–10], antimicrobial [11], anti-
oxidant [12], anti-inflammatory and analgesic effects
[12]. These medicinal benefits maybe contributed by
present of the bioactive ingredients in MK. For exam-
ples, MK has been reported to contain high amount of
polyphenolic, flavonoids, carbazole alkaloids andcoumar-
ins and flavonoids [6]. In terms of flavonoid, myricetin,
epicatechin and quercetin were the most common flavon-
oid compounds present in MK. On the other hand, gallic
acid and vanillic acid were the two most common phen-
olic acids detected in MK [13]. These antioxidant polyphe-
nolics and flavonoids that present in MK contributed to
the anti-inflammation, metal-chelating,proteasome inhibi-
tory and apoptotic effects on breast cancer cells [6]. In
terms of carbazole alkaloids, MK has been reported to
contain Girinimbine [14], mahanine [13, 15], pyrayafoline-
D and murrafoline-l [15], which contributed to the
in vitro cytotoxic effect on liver cancer cell HepG2 [16],
acute lymphoblastic T cell MOLT-3, chronic myelogenous
leukemia [8], and promyelocytic leukemia cell HL-60 [15].
Antitumor effect via induction of apoptosis and S phase
arrest [6] of MK was validated in some in vivo modelson
Dalton’s ascetic lymphoma [10], dimethyl hydrazine in-
duced colon carcinogenesis [9], and K562 challenged nude
mice [8].
Besides antitumor effect, methanolic extract of MK
leaves demonstrated a significant immunomodulatory
effect where it enhanced the phagocytic index and
increased the antibody titer against ovalbumin and protec-
tion against cyclophosphamide-induces myelosuppression
[7]. Hence, MK holds promise as an immunomodulatory
agent acting by stimulating humoral immunity and phago-
cytic function. Thus, it is interesting to evaluate the poten-
tial of MK, one of the major food flavoring ingredients in
Indian culture, in preventing incidence of breast cancer.
However, it’s potential to prevent breast cancer incident
through its antiproliferative, antiinflammatory and immu-
nomodulatory effects were not thoroughly evaluated
in vivo. We hypothesized that the progression of tumor
after inoculation in MK-treated micemay be inhibited, as
compared to the untreated in low (LR) and high risk (HR)
group mediated at least partially via immunostimulatory
effect and inflammatory reaction. Thus, this study was
aimed at evaluating the anti-inflammatory, immunomodu-
latory and chemopreventive effects of MK aqueousextract
on 4T1 challenged mice.
Methods
Sample collection and extraction
MK was obtained from the curry leaf plantation in
Selangor, Malaysia in the months of April to June 2010.
The plant was identified and deposited with a voucher
number of FRI 65673 by Science Officer Lim Chung Lu
from the Forestry Division, Forest Research Institute
Malaysia. The leaves were washed, air dried in shade,
grounded and extracted with deionized water (ratio 1:8)
at 60 °C for 2 h. The extract was filtered with Whatman
filter paper no.1 (Millipore,USA) and spray dried at an
inlet temperature of 150 °C and outlet temperature of
100 °C (Buchi B-290, Switzerland) (yield 30 % w/w). The
extract was stored at −20 °C and was used for the fol-
lowing studies.
Cell culture
Triple negative mesenchymal-like breast cancer MDA-
MB-231 (ATCC HTB-26), murine triple negative
(model for stage IV human breast cancer) cell (ATCC
CRL-2539) and murine natural killer cell sensitive
lymphoma (ATCC TIB-160) (American Type Culture
Collection) were maintained in RPMI-1640 medium
(Sigma, USA) supplemented with 10 % FBS at 37 °C and
5 % CO2.
In vitro MTT cytotoxicity assay
The assay was conducted as follow: 4T1 and MDA-
MB-231 cancer cell lines were seeded in 96-well
plates at a density of 0.5 × 104cells/well in 100 μ L
RPMI. At 24 h after seeding, the medium was re-
moved and the cells were incubated for 3 days with
RPMI-1640 in the absence or presence of various
concentrations of M. koenigii (MK) extracts. The con-
centration of the extract was 2 fold serial diluted ran-
ging between 5.00 and 0.08 mg/mL. After the
incubation period, 20 μL of MTT reagent was added
into each well. The plate was incubated again in a
CO2incubator at 37∘C for 4 h. The resulting MTT-
products were determined by measuring the absorb-
ance at 570 nm using an ELISA plate reader (BioTek,
USA) [17]. Each point represents the mean of tripli-
cate experiments. The cell viability was determined
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using the formula below and IC50 was calculated
based on the graph of viability vs absorbance.
Viability %ð Þ ¼ optical density of sample
optical density of control
 100
Animals and treatment
For in vivo chemopreventive study, 8-week old female
BALB/c mice (Total of 42 mice, n = 6 per group)
were purchased from the Animal house, Universiti
Putra Malaysia. The study was approved by the Universiti
Putra Malaysia’s Institutional Animal Care and Use
Committee (IACUC) (UPM/FPV/PS/3.2.1.551/AUP-R152).
The mice were housed in 12 h of light and dark and fed
with standard pellet and water ad libitum. Mice were oral
fed with MK (50 and 200 mg/kg body weight) or normal
saline for 30 days. Then, mice from the MK and
normal saline fed groups were randomly separated
into low (LR) and high (HR) risk cancer groups. MK
(50 and 200 mg/kg body weight) and normal saline
fed mice were inoculated with 1 × 104 4T1 cells/
mice for LR groups and 1 × 106 4T1 cells/mice for
HR groups on left mammary fat pad subcutaneously,
respectively. A group of mice without inoculation
served as normal control. MK and normal saline treat-
ment were continued until day 21 post-inoculation. After
21 days of post-inoculation, mice were sacrificed, serum
was collected for cytokines (IL1β, IL6, IL10, IL2, IFN-γ)
ELISA quantification (BioLegend, USA), spleen for
lymphocyte immunophenotyping while tumor was
harvested for histopathology and quantitative real
time PCR assay.
Measurement of tumor size
Body weight, tumorssize (with vernier calipers) and
tumor incidence were measured twice a week. Tumor
volume and tumor burden was calculated using the
following formula: tumor volume (mm3) = [(width)2 ×
length]/2 and tumor burden (%) = tumor volume (mm3)/
body weight (mg) × 100 %.
Histopathalogy study
Lungs were harvested, fixed in 10 % formaldehyde
(Sigma-Aldrich, USA) overnight, dried and viewed using
microscope to calculate the metastatic tumor nodules on
the lung [18]. Primary tumors were dissected and fixed
in 10 % formaldehyde, embedded in paraffin, cut into 2-
μm sections, and stained with hematoxylin and eosin
(H&E) [19].
Serum cytokine analysis
Serum cytokines were collected from treated and control
(untreated) mice after the mammary fat-pad implantation
and allowed to clot followed by centrifugation at 3,000xg
for 30 min, and immediately frozen and stored at −80 °C
until use. Interleukins IL-1β,IL-6, IL-10, IL-2, and
Interferon gamma (IFN-γ) levels were analyzed in the
sera collected, using the Mouse Inflammation ELISA
Strip for Profiling 8 Cytokines (Signosis BioSignal
Capture) accordingly.
Quantitative real- time PCR
RNA extraction of tumor was performed using RNeasy
mini plus kit (Qiagen, Germany) and the extracted RNA
was converted to cDNA using iScript cDNA synthesis
kit (Bio-Rad, USA). Expression of iNOS, NF-kB,iCAM
and c-MYC were evaluated using quantitative real time
PCR (qRT-PCR) SYBR select master mix (Life Tech,
USA) [20].
Nitric oxide detection
In order to quantify serum and tumor nitric oxide
(NO) level, the tumor was collected, homogenized in
ice-cold PBS and filtered through 80 μm wire mesh
(BD, USA). The filtrates were centrifuged and the
supernatant along with previously acquired serum
were subjected to nitric oxide quantification using
Griess assay (Invitrogen, USA) according to manufac-
turing protocol.
Immunophenotyping of spleen cell
Immunophenotyping of the splenocytes isolated from
the treated and untreated groups were performed using
CD4, CD3 and CD8 antibodies (Abcam, USA) via flow
cytometry (BD, USA). The differences between the con-
trol or treated group and untreated group were deter-
mined by one-way ANOVA.
Ex-vivo splenocyte cytotoxicity on Yac-1 cell
Effector cells consisted of fresh splenocytes har-
vested from the mice were co-cultured with Yac-1
(Target) cells and incubated for 18–24 h. The cyto-
toxicity of splenocytes towards Yac-1 cell line was
determined using CytoTox 96 nonradioactive cyto-
toxicity assay kit (Promega, USA) at the ratio of
effector: target of 2: 1 and 10: 1. Assays were per-
formed in triplicate and the percentage of the cyto-
toxicity was calculated according to the manufacturer
protocols.
Statistical analysis
All tests were carried out with 3 independent experi-
ments and each of the experiment consisted of 3 tech-
nical replicates. All results are expressed as Mean ±
Standard Error (S.E.M.). Significant levels (p < 0.05) were
evaluated using ANOVA test (one way) followed by post
hoc Duncan test.
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Results and discussion
MK aqueous extract exhibited cytotoxicity on breast
cancer cell lines and delay breasttumor incidence in vivo
First of all, we assessed the cytotoxic activity of MK
aqueous extracts in human and mouse breast cancer
cell lines, MDA-MB231 and 4T1 cells, respectively via
in vitro MTT cytotoxic assay. MKaqueous extract
treatment resulted in time dependent inhibition of
MDA-MB-231 (IC50 value of 2.40 ± 0.26, 0.80 ± 0.12
and 0.42 ± 0.13 mg/mL) and 4T1 cell viability (IC50
value of 1.50 ± 0.90, 0.50 ± 0.11 and 0.37 ± 0.80 mg/mL)
for 24, 48 and 72 h of treatment. Overall, MK aqueous ex-
tract possessed similar cytotoxicity against both mouse
4T1 cellsand human MDA-MB-231 cells.
Table 1 Tumor incidence and tumor burden at day 21 post 4T1 injection
Groups Day 3 Day 7 Day 10 Day 14 Day 18 Day 21
TI TB (%) TI TB (%) TI TB (%) TI TB (%) TI TB (%) TI TB (%)
Normal - - - - - - - - - - - -
LR untreated 0/6 0.00 0/6 0.00 4/6 0.10 6/6 0.42 6/6 1.00 6/6 2.11
LR MK 50 mg/kg 0/6 0.00 0/6 0.00 0/6 0.00 5/6 0.10 6/6 0.55 6/6 0.82
LR MK 200 mg/kg 0/6 0.00 0/6 0.00 0/6 0.00 0/6 0.00 5/6 0.20 6/6 0.36
HR untreated 4/6 0.03 6/6 0.33 6/6 0.84 6/6 1.30 6/6 2.11 6/6 3.65
HR MK 50 mg/kg 0/6 0.00 4/6 0.00 6/6 0.43 6/6 0.57 6/6 1.72 6/6 3.61
HR MK 200 mg/kg 0/6 0.00 0/6 0.00 4/6 0.05 5/6 0.26 6/6 0.84 6/6 2.23
TI: tumor incidence (tumor bearing mice/total mice per group); TB: tumor burden
Fig. 1 Tumor size: MK delayed the tumor formation in BALB/c mice inoculated s.c. with 4T1 cells in fat pads. The differences between groups
were determined by one-way ANOVA (∗for low risk groups while #for high risk groups; p < 0.05). Normal: normal healthy mice; LR untreated:
untreated low risk mice inoculated with 1 × 104 4T1 cell/mice; LR MK 50 mg/kg: low risk mice treated with 50 mg/kg of MK extract for 30 days
before inoculated with 1 × 1044T1 cell/mice; LR MK 200 mg/kg: low risk mice treated with 200 mg/kg of MK extract for 30 days before inoculated
with 1 × 1044T1 cell/mice; HR untreated: untreated high risk mice inoculated with 1 × 1064T1 cell/mice; HR MK 50 mg/kg: high risk mice treated
with 50 mg/kg of MK extract for 30 days before inoculated with 1 × 1064T1 cell/mice; HR MK 200 mg/kg: high risk mice treated with 200 mg/kg
of MK extract for 30 days before inoculated with 1 × 1064T1 cell/mice inoculated mice. LR: Low risk groups. HR: High risk groups
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Similar to our in vitro data, many studies have
reported the in vitro [6, 8, 16] andin vivo [8, 10, 21] anti-
tumor effect of MK [6]. However, the in vivo chemopre-
ventive and anti-tumor immunomodulatory effects were
not well evaluated. In thisstudy, in vivo pre-treatment
with MKaqueous extract in 4T1 challenged mice re-
sulted in delay tumor development (Table 1) with small
tumor size (Fig. 1) and lower tumor burden (Table 1) in
dosage dependent manner in both LR and HR groups
(Fig. 1). Although development of tumor was observed
in all 4T1 challenged mice, high concentration of MK
aqueous extract demonstrated the highest prevention
where it delayed the formation of tumor comparing to
untreated 4T1 challenged mice in both LR and HR
groups. Previous findings reported that MK methanol
extract effectively arrest the cell division at S phase
along with apoptosis inductionon MDA-MB-231 cell.
Our histological analysis revealedthat mitoses were
frequently observed in the tumors of the untreated
HR and LR groups of mice (Fig. 2). Treatment with
MK was able to reduce mitotic division in the tumors
of the LR group of mice in Fig. 2. We also observed
the lung harvested from untreated LR and HR mice
were recorded with ~23 and ~15 metastatic nodules.
200 mg/kg bw of MK aqueous extract was recorded
with significantly (p < 0.05) lower metastatic nodules,
which were ~4 and ~14 in the lung of LR and HR
mice, respectively (Table 2). Overall, high dose of MK
aqueous extract was able to reduce incidence of cell
underwent mitotic division in both LR and HR mice.
MK Aqueous extracts possess immmunomodulatary and
anti-inflammation properties by regulating several
immune-related players
Apart from antitumor effect, the immunomodulatory ef-
fect of MKon humoral and macrophage activation has
been previously evaluated [13]. However, study on the
activation of immune system to prevent tumor develop-
ment or progression are lacking. Phytochemicals such as
green tea catechin, garlic organosulfur and curcumin
that possessed anti-inflammatory and immunostimulatory
effect have been demonstrated as good chemopreventive
Fig. 2 Histological study: Histological emergence of the 4T1 tumor from LR and HR groups. Boxes indicate cells under mitotic division. Black bars
signify 200 μm (magnification 40x). The differences between the control or treated group and untreated group were determined by one-way
ANOVA (∗for low risk groups while #for high risk groups; p < 0.05). Normal: normal healthy mice; LR untreated: untreated low risk mice inoculated
with 1 × 1044T1 cell/mice; LR MK 50 mg/kg: low risk mice treated with 50 mg/kg of MK extract for 30 days before inoculated with 1 × 104 4T1
cell/mice; LR MK 200 mg/kg: low risk mice treated with 200 mg/kg of MK extract for 30 days before inoculated with 1 × 1044T1 cell/mice; HR
untreated: untreated high risk mice inoculated with 1 × 1064T1 cell/mice; HR MK 50 mg/kg: high risk mice treated with 50 mg/kg of MK extract
for 30 days before inoculated with 1 × 1064T1 cell/mice; HR MK 200 mg/kg: high risk mice treated with 200 mg/kg of MK extract for 30 days
before inoculated with 1 × 1064T1 cell/mice inoculated mice
Table 2 Lung metastasis at day 21 post 4T1 injection
Groups Number of metastatic lung nodules/mouse
Normal -*,#
LR untreated 15 ± 4
LR MK 50 mg/kg 7 ± 3*
LR MK 200 mg/kg 4 ± 2*
HR untreated 23 ± 6
HR MK 50 mg/kg 19 ± 5
HR MK 200 mg/kg 16 ± 3#
Note: Values are mean ± SEM from triplicate analyses. Data are significantly
different from LR untreated (*p < 0.05) and HR untreated (#p < 0.05) by ANOVA
and followed by Duncan test
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effect [21, 22]. Chronic inflammation and attenuation of
antitumor immunity including inhibition of cytotoxic T
lymophocyte and natural killer cell cytotoxicity were
found to support tumor outgrowth [23]. In this study,
NF-kB, iNOS, NO, IL-1β, IL-10 and IL-6 were evalu-
ated to monitor the inflammation in the untreated
and MK treated LR and HR mice. Overexpression of
NF-kB that regulates the inflammationhas been found
to promote cancer anti-apoptosis, angiogenesis and
metastasis [17]. High dose of MKaqueous extract had
the highest reduction of the NF-kB in LR group
(Fig. 3). NF-kB can be activated by proinflammatory
Fig. 3 Quantitative real time PCR: Quantitative real timePCR evaluation on expression of tumor iNOS, NF-kB, c-MYC and iCAM of MK (50 and
200 mg/kg) treated and untreated mice. The statistical differences among all groups were assessed by one-way ANOVA followed by Duncan
post-hoc. The differences between the control or treated group and untreated group were determined by one-way ANOVA (∗p < 0.05). Normal:
normal healthy mice; LR untreated: untreated low risk mice inoculated with 1 × 1044T1 cell/mice; LR MK 50 mg/kg: low risk mice treated with
50 mg/kg of MK extract for 30 days before inoculated with 1 × 1044T1 cell/mice; LR MK 200 mg/kg: low risk mice treated with 200 mg/kg of MK
extract for 30 days before inoculated with 1 × 1044T1 cell/mice; HR untreated: untreated high risk mice inoculated with 1 × 1064T1 cell/mice; HR
MK 50 mg/kg: high risk mice treated with 50 mg/kg of MK extract for 30 days before inoculated with 1 × 1064T1 cell/mice; HR MK 200 mg/kg:
high risk mice treated with 200 mg/kg of MK extract for 30 days before inoculated with 1 × 1064T1 cell/mice inoculated mice. LR: Low risk groups.
HR: High risk groups
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cytokineIL-1β and pleiotropic cytokine IL-6. IL-6
stimulated breast cancer cell proliferation, anti-apoptotic
effect, motility and invasion thus promote progression of
breast cancer [24]. On the other hand, the immunosup-
pressive cytokine IL-10 has been reported with both pro
and anti-tumor effect [25]. Generally, elevated level of
serum IL-6 and IL-10 were found to correlate strongly
with the breast cancer clinical stage especially in the meta-
static estrogen receptor negative breast cancer [26, 27]. El-
evated level of serum IL-1β, IL-6 and IL-10 were observed
in untreated LR and HR mice comparing to normal con-
trol. Our findings show that the inflammatory mediator
IL-6, proinflammatory cytokine IL-1β and immunosup-
pressive cytokine IL-10 in serum levels were reduced in
MK-treated 4T1 inoculated mice especially in the LR
group (Fig. 4). Subsequently, high dose of MKaqueous ex-
tract had the highest reduction of iNOS in HR group
(Fig. 3). iNOS catalyzes oxidative deamination of l-
arginine to produce the pro-inflammatory mediator NO.
Raised of NO involved in promotion of extreme oxidation,
tumor progression and angiogenesis [28]. The presence of
inflammation in the serum and tumor was measured by
NO quantification. Figure 5 showed that the progression
of cancer was linked with higher levels of NO in both
serum and tumor. MK-treatments successfully reduced
the NO levels in both the spleen and tumor of both the
LR and HR groups of tumor. Previous reporthas shown
that methanol extract of MK possessed anti-inflammatory
effect [12]. From our current study, it indicates that
MKaqueous extract effectively reduced inflammation me-
diators and cytokines, which help to delay the progression
of breast cancer especially in the LR mice. Metastatic nod-
ules reduction in the lung harvested from MK aqueous ex-
tract mice in both LR and HR groups further confirmed it.
The metastasis incident was further supported by the ex-
pression of iCAM in tumor, which was evaluated by quan-
titative real time PCR. iCAM is an adhesion molecule in
the immunoglobulin superfamily correlated with meta-
static potential where its over-expression promotes trans-
endothelial migration of the cancer cell [29]. iCAM
expression was significantly downregulated in the tumor
of MK-treated LR mice (Fig. 3), which contributed to the
control of primary tumor progression and metastasis of
tumor by the extract.
Overexpression of c-MYC was found to drive cellular
proliferation thus promote tumorigenesis whereas down-
regulation of c-MYC can help to restore cellular senes-
cence and thus promote tumor regression [30]. In line
with our finding, c-MYC expression was found to be ef-
fectively downregulated in MKaqueous extract treated
LR mice (Fig. 3). This study proposes that delay of 4T1
cancer progression in LR mice by MK aqueous extract
might be contributed by the cell cycle arrest in the
dosage dependent manner as supported by the histology
analysis and c-MYC expression. Nevertheless, other
factors could add to its chemopreventive effect since the
c-MYC expression in HR group was not much different
than untreated mice.
Fig. 4 Serum levels ofIL1β, IL6, IL10, IL2, IFN-γ (pg/mL) from different treatment groups on day 21 after 4T1 cell inoculation. Each value represents
the means ± S.D. for three mice in triplicate each. The differences between the control or treated group and untreated group were determined
by one-way ANOVA (∗for low risk groups while #for high risk groups; p < 0.05). Normal: normal healthy mice; LR untreated: untreated low risk
mice inoculated with 1 × 1044T1 cell/mice; LR MK 50 mg/kg: low risk mice treated with 50 mg/kg of MK extract for 30 days before inoculated with
1 × 1044T1 cell/mice; LR MK 200 mg/kg: low risk mice treated with 200 mg/kg of MK extract for 30 days before inoculated with 1 × 1044T1 cell/
mice; HR untreated: untreated high risk mice inoculated with 1 × 1064T1 cell/mice; HR MK 50 mg/kg: high risk mice treated with 50 mg/kg of MK
extract for 30 days before inoculated with 1 × 1064T1 cell/mice; HR MK 200 mg/kg: high risk mice treated with 200 mg/kg of MK extract for
30 days before inoculated with 1 × 1064T1 cell/mice inoculated mice. LR: Low risk groups. HR: High risk groups
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Additionally, MK was also able to restore the produc-
tion of both IL-2 and IFN-γ in the LR group of mice
and high dose of MK in HR group, whereas no signifi-
cant changes at low dose of HR group (Fig. 4). IL-2 is
the T helper 1 (Th1) cytokines that promote CD8 CTL
proliferation and cytolytic activity against cancer. On the
other hand, type II interferon IFN-γ produced by acti-
vated CD8 CTL to inhibit angiogenesis, promote CTL
and NK cell cytotoxicity, positively feedback on the Th1
immunity while suppress Th2 cell differentiation and
promote tumor eradication via apoptosis [23]. The treat-
ment of MK in vivo managed to increase the level of
Fig. 6 Immunophenotyping: CD4 and CD8 immunophenotyping of samples from different treatment groups on day 21 after 4T1 cell inoculation.
Each value represents the means ± S.D. for three mice in triplicate each. The differences between the control or treated group and untreated group
were determined by one-way ANOVA (∗for low risk groups while #for high risk groups; p < 0.05). Normal: normal healthy mice; LR untreated: untreated
low risk mice inoculated with 1 × 1044T1 cell/mice; LR MK 50 mg/kg: low risk mice treated with 50 mg/kg of MK extract for 30 days before inoculated
with 1 × 1044T1 cell/mice; LR MK 200 mg/kg: low risk mice treated with 200 mg/kg of MK extract for 30 days before inoculated with
1 × 1044T1 cell/mice; HR untreated: untreated high risk mice inoculated with 1 × 1064T1 cell/mice; HR MK 50 mg/kg: high risk mice treated
with 50 mg/kg of MK extract for 30 days before inoculated with 1 × 1064T1 cell/mice; HR MK 200 mg/kg: high risk mice treated with 200 mg/kg of MK
extract for 30 days before inoculated with 1 × 1064T1 cell/mice inoculated mice. LR: Low risk groups. HR: High risk groups
Fig. 5 NO level: NO level of tumor and spleen homogenate from different treatment groups on day 21 following 4T1 cell inoculation. Each value
represents the means ± S.D. for three mice in triplicate each. The differences between the control or treated group and untreated group were
determined by one-way ANOVA (∗for low risk groups while #for high risk groups; p < 0.05). Normal: normal healthy mice; LR untreated: untreated
low risk mice inoculated with 1 × 1044T1 cell/mice; LR MK 50 mg/kg: low risk mice treated with 50 mg/kg of MK extract for 30 days
before inoculated with 1 × 1044T1 cell/mice; LR MK 200 mg/kg: low risk mice treated with 200 mg/kg of MK extract for 30 days before
inoculated with 1 × 1044T1 cell/mice; HR untreated: untreated high risk mice inoculated with 1 × 1064T1 cell/mice; HR MK 50 mg/kg:
high risk mice treated with 50 mg/kg of MK extract for 30 days before inoculated with 1 × 1064T1 cell/mice; HR MK 200 mg/kg: high
risk mice treated with 200 mg/kg of MK extract for 30 days before inoculated with 1 × 1064T1 cell/mice inoculated mice. LR: Low risk
groups. HR: High risk groups
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both CD8 CTLs and CD4 T cells in both the HR and
LR groups (Fig. 6). Increment of ex-vivo cytotoxicity
against 4T1 cells indicates the improvement of antitu-
mor immunity. Co-cultivation of splenocyte with Yac-
1 cell was used to evaluate the cytotoxicity of the
splenocyte on day 21 following inoculation of 4T1
cell. A higher ratio of effector (splenocytes) was asso-
ciated with greater cytotoxicity against 4T1 cells.
However, this effect was significantly (P< 0.05) lower
in the untreated mice. Treatments with MK was able
to enhance splenocyte cytotoxicity against 4T1 cells
in LR mice while in HR group, treatment with high
dose of MK was able to slightly enhance the spleno-
cyte cytotoxicity as compared to the untreated group
of mice as shown in Fig. 7. In general, higher level of
antitumor serum cytokines (IL-2 and IFN-γ) (Fig. 4)
associated with improved splenocyte cytotoxicity against
4T1 cells (Fig. 7) were observed in MK-treated mice
in dosage dependent manner. Better recovery on the
antitumor immunity was observed in LR mice than
the HR mice treated with the extract. This signifies
that chemoprevention of high dose of extract in HR
mice maybe contributed by its immunostimulatory
effect. On the other hand, the extract effectively
controls the progression of 4T1 in LR mice by its
antiproliferation, antiinflammation and immunomodu-
lation effects.
Conclusion
MKaqueous extract had demonstrated chemopreventive
effects on 4T1 challenged mice contributed by the cyto-
toxicity, anti-inflammatory and immunomodulatory ef-
fects. Moreover, MK aqueous extract has delayed the
formation of breast cancer and reduced the mitotic div-
ision of the tumor through stimulation of T cell cytokine
production (IL-2 and IFN-γ) and cytotoxicity. Here we
show that MKaqueous extract possessed potential
chemopreventive effect especially on the LR of breast
cancer.
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